223 related articles for article (PubMed ID: 23294554)
1. Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
Miranda-Filloy JA; López-Mejias R; Genre F; Carnero-López B; Ochoa R; Diaz de Terán T; González-Juanatey C; Blanco R; Llorca J; González-Gay MA
Clin Exp Rheumatol; 2013; 31(3):365-71. PubMed ID: 23294554
[TBL] [Abstract][Full Text] [Related]
2. Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
Miranda-Filloy JA; López-Mejias R; Genre F; Carnero-López B; Ochoa R; Diaz de Terán T; González-Juanatey C; Blanco R; Llorca J; González-Gay MA
Clin Exp Rheumatol; 2013; 31(4):538-45. PubMed ID: 23711190
[TBL] [Abstract][Full Text] [Related]
3. Correlation between insulin resistance and serum ghrelin in non-diabetic ankylosing spondylitis patients undergoing anti-TNF-α therapy.
Genre F; López-Mejías R; Miranda-Filloy JA; Carnero-López B; Gómez-Acebo I; Blanco R; Ochoa R; Rueda J; González-Juanatey C; Llorca J; González-Gay MÁ
Clin Exp Rheumatol; 2013; 31(6):913-8. PubMed ID: 23981480
[TBL] [Abstract][Full Text] [Related]
4. Apelin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
Genre F; Miranda-Filloy JA; López-Mejias R; Carnero-López B; Ochoa R; Rueda J; González-Juanatey C; Blanco R; Llorca J; González-Gay MA
Clin Exp Rheumatol; 2013; 31(4):532-7. PubMed ID: 23484462
[TBL] [Abstract][Full Text] [Related]
5. Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
Genre F; López-Mejías R; Miranda-Filloy JA; Ubilla B; Carnero-López B; Palmou-Fontana N; Gómez-Acebo I; Blanco R; Rueda-Gotor J; Pina T; González-Juanatey C; Llorca J; González-Gay MÁ
Clin Exp Rheumatol; 2014; 32(5):640-6. PubMed ID: 25190453
[TBL] [Abstract][Full Text] [Related]
6. Correlation between two biomarkers of atherosclerosis, osteopontin and angiopoietin-2, in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
Genre F; López-Mejías R; Miranda-Filloy JA; Ubilla B; Carnero-López B; Gómez-Acebo I; Blanco R; Ochoa R; Arias-Bajo M; Rueda-Gotor J; Paz-Carreira J; González-Juanatey C; Llorca J; González-Gay MA
Clin Exp Rheumatol; 2014; 32(2):231-6. PubMed ID: 24295386
[TBL] [Abstract][Full Text] [Related]
7. Asymmetric dimethylarginine serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
Genre F; López-Mejías R; Miranda-Filloy JA; Carnero-López B; Gómez-Acebo I; Blanco R; Ochoa R; Rueda J; González-Juanatey C; Llorca J; González-Gay MA
Clin Exp Rheumatol; 2013; 31(5):749-55. PubMed ID: 23806325
[TBL] [Abstract][Full Text] [Related]
8. Leptin and adiponectin levels in patients with ankylosing spondylitis. The effect of infliximab treatment.
Derdemezis CS; Filippatos TD; Voulgari PV; Tselepis AD; Drosos AA; Kiortsis DN
Clin Exp Rheumatol; 2010; 28(6):880-3. PubMed ID: 21122270
[TBL] [Abstract][Full Text] [Related]
9. Gelsolin levels are decreased in ankylosing spondylitis patients undergoing anti-TNF-alpha therapy.
Genre F; López-Mejías R; Miranda-Filloy JA; Ubilla B; Carnero-López B; Gómez-Acebo I; Blanco R; Ochoa R; Rueda-Gotor J; González-Juanatey C; Llorca J; González-Gay MA
Clin Exp Rheumatol; 2014; 32(2):218-24. PubMed ID: 24351434
[TBL] [Abstract][Full Text] [Related]
10. Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy.
Gonzalez-Gay MA; Vazquez-Rodriguez TR; Garcia-Unzueta MT; Berja A; Miranda-Filloy JA; de Matias JM; Gonzalez-Juanatey C; Llorca J
Clin Exp Rheumatol; 2010; 28(1):56-62. PubMed ID: 20346239
[TBL] [Abstract][Full Text] [Related]
11. TNF-alpha antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients.
Miranda-Filloy JA; Llorca J; Carnero-López B; González-Juanatey C; Blanco R; González-Gay MA
Clin Exp Rheumatol; 2012; 30(6):850-5. PubMed ID: 22765845
[TBL] [Abstract][Full Text] [Related]
12. Anti-TNF-α therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients.
Genre F; López-Mejías R; Miranda-Filloy JA; Ubilla B; Mijares V; Carnero-López B; Gómez-Acebo I; Dierssen-Sotos T; Remuzgo-Martínez S; Blanco R; Pina T; González-Juanatey C; Llorca J; González-Gay MA
Rheumatol Int; 2015 Dec; 35(12):2069-78. PubMed ID: 26143161
[TBL] [Abstract][Full Text] [Related]
13. Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis.
Gonzalez-Gay MA; Garcia-Unzueta MT; Gonzalez-Juanatey C; Miranda-Filloy JA; Vazquez-Rodriguez TR; De Matias JM; Martin J; Dessein PH; Llorca J
Clin Exp Rheumatol; 2008; 26(2):311-6. PubMed ID: 18565254
[TBL] [Abstract][Full Text] [Related]
14. High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis.
Gonzalez-Gay MA; Llorca J; Garcia-Unzueta MT; Gonzalez-Juanatey C; De Matias JM; Martin J; Redelinghuys M; Woodiwiss AJ; Norton GR; Dessein PH
Clin Exp Rheumatol; 2008; 26(4):596-603. PubMed ID: 18799090
[TBL] [Abstract][Full Text] [Related]
15. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
[TBL] [Abstract][Full Text] [Related]
16. The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease.
Karmiris K; Koutroubakis IE; Xidakis C; Polychronaki M; Kouroumalis EA
Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):789-94. PubMed ID: 17700265
[TBL] [Abstract][Full Text] [Related]
17. Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis.
Gonzalez-Gay MA; Garcia-Unzueta MT; Berja A; Gonzalez-Juanatey C; Miranda-Filloy JA; Vazquez-Rodriguez TR; de Matias JM; Martin J; Dessein PH; Llorca J
Clin Exp Rheumatol; 2009; 27(2):222-8. PubMed ID: 19473561
[TBL] [Abstract][Full Text] [Related]
18. Patients with ankylosing spondylitis and low disease activity because of anti-TNF-alpha therapy have higher TRAIL levels than controls: a potential compensatory effect.
Genre F; López-Mejías R; Rueda-Gotor J; Miranda-Filloy JA; Ubilla B; Carnero-López B; Palmou-Fontana N; Gómez-Acebo I; Blanco R; Pina T; Ochoa R; González-Juanatey C; Llorca J; González-Gay MA
Mediators Inflamm; 2014; 2014():798060. PubMed ID: 24976690
[TBL] [Abstract][Full Text] [Related]
19. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
[TBL] [Abstract][Full Text] [Related]
20. Relationship of leptin with adiposity and inflammation and resistin with disease severity in psoriatic patients undergoing anti-TNF-alpha therapy.
Pina T; Genre F; Lopez-Mejias R; Armesto S; Ubilla B; Mijares V; Dierssen-Sotos T; Gonzalez-Lopez MA; Gonzalez-Vela MC; Blanco R; Hernández JL; Llorca J; Gonzalez-Gay MA
J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1995-2001. PubMed ID: 25823684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]